1299 Radiomics features to predict tumor response and biomarker status in non-small cell lung cancer (NSCLC) patients treated with immunotherapy

Similar Items

• 1298 Radiomics features to predict immune checkpoint inhibitor-related pneumonitis (CIP) in NSCLC patients treated with immunotherapy
  by: Young Kwang Chae, et al.
  Published: (2023-11-01)
• 38 Serum proteomics signature and its association with immune-related toxicities and survival in patients with non-small cell lung cancers (NSCLC) receiving immunotherapy
  by: Young Kwang Chae, et al.
  Published: (2023-11-01)
• Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review
  by: Youjin Oh, et al.
  Published: (2024-01-01)
• E.C. Dijkhof, J.G. Kruisheer, Oorkondenboek van Holland en Zeeland tot 1299, V, 1291 tot 1299
  by: W. Prevenier
  Published: (2007-01-01)
• E.C. Dijkhof, J.G. Kruisheer, Oorkondenboek van Holland en Zeeland tot 1299, V, 1291 tot 1299
  by: W. Prevenier
  Published: (2007-01-01)